GenomOncology has entered into a strategic partnership with WeTrials to help patients with Central Nervous System Cancer access and enroll in clinical trials more efficiently. The collaboration integrates WeTrials’ AI-powered patient engagement platform with GenomOncology’s precision medicine software, enabling clinicians to connect genomic insights with relevant clinical trial opportunities more seamlessly.

The partnership also builds upon GenomOncology’s existing collaboration with Belay Diagnostics, creating a more integrated pathway from molecular diagnosis to clinical trial enrollment. Earlier this year, Belay Diagnostics incorporated GenomOncology’s GO Pathology Workbench into its variant interpretation workflow for the Summit 2.0 liquid biopsy test, a cerebrospinal fluid-based assay designed to support diagnosis and management of primary and secondary central nervous system malignancies.

Under the new initiative, the GO Genomic Report generated through this workflow will now include a direct link to the WeTrials platform. This feature allows clinicians to transition directly from a patient’s molecular report—including trial recommendations identified by GenomOncology—to WeTrials’ patient-friendly trial information pages. The platform simplifies complex clinical trial details and enables patients to explore participation options more easily.

The integration aims to reduce barriers that often delay clinical trial participation by providing a streamlined pathway from diagnosis to enrollment. By connecting genomic data, diagnostic insights and patient engagement tools, the companies aim to ensure that patients are informed about potential clinical trials earlier in their treatment journey.

Initially, the partnership will focus on patients with central nervous system cancers who undergo testing through Belay Diagnostics. Over time, the companies plan to expand the initiative to additional diagnostic partners and other cancer types, further broadening access to clinical trials for oncology patients.

Through this collaboration, GenomOncology, WeTrials and Belay Diagnostics aim to create a more efficient ecosystem that links molecular diagnostics with trial enrollment, helping patients gain faster access to innovative therapies and advancing precision medicine in oncology.